SEC-sourced researchBeta

DNA

Ginkgo Bioworks Holdings, Inc.

US markets

Data passport

CIK: 0001830214
Exchange: NYSE
Business activity: — · SIC 2836
Financial inputs: 6/6
Filing date: Oct 7, 2026
SEC registry record: Operating company

Last updated: Oct 8, 2026, 9:09 AM UTCSEC company ticker catalog ↗SEC Financial Statement Data Sets ↗SEC investment company series and class registry ↗

Annual financial history

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.

Chart metric

DNA · Exact amounts and source periods · USD
Period end	Revenue	Filing date
December 2023	251,455,000.0000	Feb 26, 2026
December 2024	227,043,000.0000	Feb 26, 2026
December 2025	170,155,000.0000	Feb 26, 2026

Annual periods · USD

Period end	Revenue	Net income	Operating cash flow	Total assets	Total liabilities	Filing date
December 2025	170,155,000.0000	-312,763,000.0000	-171,059,000.0000	1,119,696,000.0000	611,106,000.0000	Feb 26, 2026
December 2024	227,043,000.0000	-547,029,000.0000	-319,585,000.0000	1,377,449,000.0000	661,391,000.0000	Feb 26, 2026
December 2023	251,455,000.0000	-892,869,000.0000	-295,500,000.0000	—	—	Feb 26, 2026

Financial inputs behind the calculation

Financial inputs	USD	Period end	Filing date	Form
RevenueRevenueFromContractWithCustomerExcludingAssessedTax	$170.16M	December 2025	Feb 26, 2026	10-K
Previous period revenueRevenueFromContractWithCustomerExcludingAssessedTax	$227.04M	December 2024	Feb 26, 2026	10-K
Net incomeNetIncomeLoss	-$312.76M	December 2025	Feb 26, 2026	10-K
Operating cash flowNetCashProvidedByUsedInOperatingActivities	-$171.06M	December 2025	Feb 26, 2026	10-K
Total assetsAssets	$1.12B	December 2025	Feb 26, 2026	10-K
Total liabilitiesLiabilities	$611.11M	December 2025	Feb 26, 2026	10-K

New filings

Explore methodology ↗